timothy sykes logo

Stock News

BridgeBio’s Triumph: Is It Too Late to Buy?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
BridgeBio’s Triumph: Is It Too Late to Buy? Thumbnail

BridgeBio Pharma Inc.’s stock has been trading up by 8.72 percent following promising FDA news boosting investor confidence.

Recent Developments

  • Acoramidis, BridgeBio Pharma’s promising drug aimed at treating transthyretin amyloidosis with cardiomyopathy, recently gained UK marketing authorization, marking it a significant win for the company.

  • Analysts at Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and a $50 target, highlighting the promising therapy potential for transthyretin amyloidosis with cardiomyopathy.

  • A Phase 3 trial of acoramidis demonstrated significant improvement in clinical outcomes, reducing mortality and first hospitalization risks in patients with transthyretin amyloid cardiomyopathy.

  • BridgeBio’s management is scheduled to meet with Piper Sandler, projecting an opportunity to showcase their future strategies and financial roadmap to a leading investment firm.

  • Positive receptiveness for acoramidis has led analyst Raghuram Selvaraju to increase the target price to $53, expressing confidence in BridgeBio’s potential success.

Candlestick Chart

Live Update At 17:03:09 EST: On Tuesday, April 29, 2025 BridgeBio Pharma Inc. stock [NASDAQ: BBIO] is trending up by 8.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Market Performance and Financial Overview

As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” Many traders get caught up in the allure of quick profits and high-risk trades, but the key to long-term success in trading lies in disciplined practices and consistent growth. By focusing on steady progress rather than high-stakes gambles, traders can achieve sustainable wealth over time.

BridgeBio Pharma Inc. has had quite a run lately, capturing the industry’s attention with its strategic movements and clinical successes. The recent approval of their drug, acoramidis, in the UK can potentially pave the way for healthier balance sheets, augmented by royalties from international sales. In addition, the company leverages strategic partnerships, such as the agreement with Bayer for handling commercial activities abroad. This could significantly boost its financial performance.

In recent trades, BBBIO’s share prices have exhibited an encouraging upward trend. On a single day, share prices opened at $36.05 and closed at $36.42, indicating a stable trajectory influenced by the new developments. Financial statements reveal BridgeBio’s aggressive endeavor in R&D, evidenced by the high research expense recorded. This signifies a strategic intent to spearhead innovation and pipeline growth.

More Breaking News

Key financial ratios also paint a challenging landscape. Although the gross margin is high at 98.3%, negative values in operating, pre-tax, and net margins indicate profitability challenges. Bridging this gap may hinge on the continued success of products like acoramidis and global market penetration.

The Role of Recent Announcements

Research analysts’ positive sentiments add a feather to BridgeBio’s cap. Redburn Atlantic’s Buy rating and $50 target echo optimism in the drug pipeline’s potential. Additionally, their assessment reflects the vibrant potential market for therapies targeting transthyretin amyloidosis with cardiomyopathy.

Excitement doesn’t stop there! The results from the recent phase 3 ATTR-CM trial lend validation to the stock’s recent surge. Showing significant improvements in clinical outcomes, the results underscore the drug candidate’s medical importance, strengthening BridgeBio’s standing amidst investors and clinicians alike.

Another strategic maneuver involves their scheduled meetings with Piper Sandler. While merely presentations, these sessions could lead to an influx of investor interest, bolstering financial backing and confidence from the investor community, enhancing the company’s appeal.

Speaking of analysts, Raghuram Selvaraju at H.C. Wainwright shines a favorable spotlight on the drug’s early reception. Their increased price target underscores assuredness in potential market performance, signaling that attractive gains could be on the horizon.

Conclusion: Stepping Back to the Bigger Picture

BridgeBio Pharma’s journey has unfolded with meticulous strides toward delivering impactful healthcare solutions. While uncertainties remain due to the high negative profit margins and ratios, the confluence of positive news hints at a promising future.

As share prices nudge upward, potential traders and current stakeholders might ponder if it’s too late to jump in; however, the fundamental question isn’t whether the momentum will continue but how effectively BridgeBio can leverage its developments to ensure sustainable growth. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” Thus, maintaining a disciplined approach can be crucial for those involved with BridgeBio.

Amidst the landscape of biopharmaceuticals, BridgeBio is delicately weaving a narrative of resilience, expansion, and transformation. Traders should watch closely, as the story of BridgeBio and its innovative pursuits is only just beginning.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”